EUVIMEDEUVIMED entdecken
Open Access

DHODH inhibition alters T cell metabolism limiting acute graft-versus - host disease while retaining graft- versus - leukemia response

Rathan Kumar iD, Kara M Braunreiter iD, Lotus Neidemire-Colley iD, Natalie Sell, Yandi Gao, Camryn Steere, Margot Weber, Dhruva Vanakeri, Eunice Choi, Hannah K Choe iD, Sandip Vibhute, Chad Bennett und 6 weitere

The Journal of Immunology · 2025

DOI: 10.1093/jimmun/vkaf023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, 2025. Verfasst von Rathan Kumar und 17 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States. Hauptthemen laut MEDLINE: Graft vs Host Disease, Graft vs Leukemia Effect, Oxidoreductases Acting on CH-CH Group Donors, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Paula and Rodger Riney Foundation, NIH HHS, Ohio State University Comprehensive Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute graft-versus-host disease (GVHD) is a donor T cell driven complication and the leading cause of non-relapse mortality in patients receiving an allogeneic hematopoietic cell transplantation (allo-HCT). Allogeneic donor T cells eradicate residual leukemia and prevent relapse via the graft-versus-leukemia (GVL) effect and are critical for responding against opportunistic infections post-transplant. Current regimens successful in preventing GVHD are broadly immunosuppressive and come at the cost of increased risk of relapse and/or infection. Therefore, there is an urgent need for new approaches that limit GVHD while retaining GVL responses. During GVHD, alloreactive T cells boost their energy production through oxidative phosphorylation (OXPHOS) and glycolysis, supporting heightened proliferation and pathogenicity against healthy host tissues. The enzyme dihydroorate dehydrogenase (DHODH), is essential for de novo pyrimidine biosynthesis and for maintaining mitochondrial membrane potential during OXPHOS. Having shown upregulation of DHODH messenger RNA and protein expression in activated human T cells, we evaluated DHODH inhibition, via a small molecule inhibitor HOSU-53, as a therapeutic approach for GVHD. Inhibiting DHODH significantly reduced oxidative metabolism in T cells both during and after activation, while selectively suppressing inflammatory cytokine production in de novo activated, but not previously activated, T cells. In a xenogeneic model, HOSU-53 treatment limited GVHD severity, decreased pathogenic Th1 and Th17 response, and preserved beneficial GVL effects. Altogether, we identify DHODH inhibition as an innovative treatment strategy in allo-HCT recipients to reduce GVHD severity and retain effective GVL response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseGraft vs Leukemia EffectOxidoreductases Acting on CH-CH Group DonorsHematopoietic Stem Cell TransplantationT-LymphocytesAnimalsHumansMiceDihydroorotate DehydrogenaseOxidative PhosphorylationAcute DiseaseTransplantation, Homologous

Stichwörter der Autor:innen

DHODHGVHDmetabolism

Substanzen

Oxidoreductases Acting on CH-CH Group DonorsDihydroorotate Dehydrogenase

Autor:innen und Institutionen

  • Division of Hematology, Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States.
  • Department of Pathology, Michael E. DeBakey VA Medical Center, Houston, TX, United States.
  • Drug Discovery Shared Resource, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States.
  • Drug Development Institute, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, United States.
  • Division of Blood and Marrow Transplantation & Cellular Therapy, University of Minnesota, Minneapolis, MN, United States.
  • Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, United States.

ORCID-Profile: Rathan Kumar, Kara M Braunreiter, Lotus Neidemire-Colley, Hannah K Choe

Förderung

  • Paula and Rodger Riney Foundation
  • NIH HHS
  • Ohio State University Comprehensive Cancer Center
  • NCI NIH HHS
  • The OSUCCC Drug Development Institute
  • American Cancer Society Research Scholar
  • OSU CCC and Division of Hematology start-up funds
  • OSUCCC Drug Development Institute

Zitieren

APA

Kumar, R., Braunreiter, K. M., Neidemire-Colley, L., Sell, N., Gao, Y., Steere, C., Weber, M., Vanakeri, D., Choi, E., Choe, H. K., Vibhute, S., Bennett, C., Byersdorfer, C. A., Elgamal, O. A., Goodwin, T. E., Hertlein, E. K., Byrd, J. C., & Ranganathan, P. (2025). DHODH inhibition alters T cell metabolism limiting acute graft-versus - host disease while retaining graft- versus - leukemia response. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf023

Vancouver

Kumar R, Braunreiter KM, Neidemire-Colley L, Sell N, Gao Y, Steere C, et al. DHODH inhibition alters T cell metabolism limiting acute graft-versus - host disease while retaining graft- versus - leukemia response. The Journal of Immunology. 2025. doi:10.1093/jimmun/vkaf023

BibTeX
@article{Kumar2025,
  author = {Kumar, Rathan and Braunreiter, Kara M and Neidemire-Colley, Lotus and Sell, Natalie and Gao, Yandi and Steere, Camryn and Weber, Margot and Vanakeri, Dhruva and Choi, Eunice and Choe, Hannah K and Vibhute, Sandip and Bennett, Chad and Byersdorfer, Craig A and Elgamal, Ola A and Goodwin, Thomas E and Hertlein, Erin K and Byrd, John C and Ranganathan, Parvathi},
  title = {DHODH inhibition alters T cell metabolism limiting acute graft-versus - host disease while retaining graft- versus - leukemia response},
  journal = {The Journal of Immunology},
  year = {2025},
  doi = {10.1093/jimmun/vkaf023}
}
Kostenlos starten →